
IRON Stock Forecast & Price Target
IRON Analyst Ratings
Bulls say
Disc Medicine is a promising biopharmaceutical company with multiple potential sources of upside, including their pipeline candidate DISC-3405, which is showing strong results in their Phase 2 study for polycythemia vera (PV). In addition, their lead candidate bitopertin has received FDA alignment for accelerated approval in treating erythropoietic protoporphyria (EPP), and management is confident in their ability to meet the timeline for potential approval in 2027. With a diverse pipeline and positive feedback from treating physicians, Disc Medicine has the potential for long-term success and a potential price target of $120 per share.
Bears say
Disc Medicine is seeing promising results from its latest Phase 2 data for its lead drug selcodebart, showing a 56% major anemia response rate and a 72% overall response rate across patients with anemia from myelofibrosis. Furthermore, the company plans to hold an end-of-Phase 2 meeting with the FDA by year-end to discuss the path towards registration and has ongoing studies for additional indications. However, with a high valuation based on future sales projections and limited treatment options for myelofibrosis-associated anemia, there is considerable risk for this clinical-stage company.
This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares